As of Friday close, Royalty Pharma plc’s (NASDAQ:RPRX) stock was down -$0.17, moving down -0.49 percent to $34.64. The average number of shares traded per day over the past five days has been 3,221,780 shares. 4 times new highs have been achieved over the past 5 days, with a $1.54 gain in that time frame. In the last twenty days, the average volume was 2,332,020, while in the previous 50 days, it was 1,904,630.
Since last month, RPRX stock retreated -8.09%. Shares of the company fell to $32.68 on 03/13/23, the lowest level in the past month. A 52-week high of $44.75 was reached on 01/03/23 after having rallying from a 52-week low of $32.68. Since the beginning of this year, RPRX’s stock price has dropped by -12.35% or -$4.88, and marked a new high 1 time. However, the stock has declined by -22.59% since its 52-week high.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
RPRX stock investors should be aware that Royalty Pharma plc (RPRX) stock had its last reported insider trading activity 23 days ago on Feb 23. Lloyd George W., the EVP, Investments & CLO of the company, disposed of 25,000 shares for $37.27 on Feb 23. It resulted in a $931,658 divestment by the insider. Urist Marshall sold 23,333 shares at an average price of $37.30 on Feb 22. The insider now owns 46,667 shares following the transaction. On Dec 09, Director RIGGS RORY B sold 19,990 shares at $42.07 apiece. The transaction was valued at $840,939.
Right now, Royalty Pharma plc (RPRX) has a P/E ratio of about 314.91. Besides these, the trailing price-to-sales (P/S) ratio of 9.52, the price-to-book (PB) ratio of 2.72, and the price-to-cash flow ratio of 308.27 may also be considered.
The latest dividend of $0.20 per share was paid out, which is 5.26% more than last year’s $0.19. On Monday January 9 2023, a $0.01 dividend increase was announced.
In the three months ended September 29, Royalty Pharma plc’s quick ratio stood at 2.20, while its current ratio was 2.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 1.09, and the total debt-to-equity ratio was 1.26. In the year ended September 29, operating margins totaled 13.70%. Based on annual data, RPRX earned $1.93 billion in gross profit and brought in $2.24 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 2.40%. Return on equity (ROE) for the past 12 months was 0.70%.
In Royalty Pharma plc’s quarter-end financial report for September 29, it reported total debt of $6.12 billion against cash and short-term investments of $1.3 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RPRX’s revenue fell -1.76% to $573.46 million during the quarter, while net income inched up to $565.75 million. While analysts expected Royalty Pharma plc to report $0.72 quarterly earnings, the actual figure was $0.72 per share. During the quarter, the company generated -$477.32 million in EBITDA. The liabilities of Royalty Pharma plc were 7.29 billion at the end of its most recent quarter ended September 29, and its total debt was $7.11 billion. The value of shareholders’ equity is $607.22 million.
This quick technical analysis looks at Royalty Pharma plc’s (RPRX) price momentum. With a historical volatility rate of 29.76%, the RSI 9-day stood at 46.14% on 17 March.
With respect to its five-day moving average, the current Royalty Pharma plc price is up by +4.65% percent or $1.54. At present, RPRX shares trade -6.98% below its 20-day simple moving average and -15.55% percent below its 100-day simple moving average. However, the stock is currently trading approximately -11.52% below its SMA50 and -15.80% below its SMA200.
Stochastic coefficient K was 49.91% and Stochastic coefficient D was 34.55%, while ATR was 0.77. Given the Stochastic reading of 54.44% for the 14-day period, the RSI (14) reading has been calculated as 40.70%. As of today, the MACD Oscillator reading stands at 0.73, while the 14-day reading stands at 0.16.
Royalty Pharma plc (RPRX) has been rated Buy by analysts. According to 0 brokerage firms, RPRX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Royalty Pharma plc stock as buy, with 8 recommending it as overweight.
With a median target price of $52.50, the current consensus forecast for the stock is $47.00 – $60.00. Based on these forecasts, analysts predict Royalty Pharma plc (RPRX) will achieve an average price target of $52.88.